{'52WeekChange': 0.5449827,
 'SandP52WeekChange': None,
 'address1': '2 Holzman Street',
 'address2': 'Science Park PO Box 4081',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.1,
 'askSize': 800,
 'averageDailyVolume10Day': 107337,
 'averageVolume': 149373,
 'averageVolume10days': 107337,
 'beta': 0.49692,
 'beta3Year': None,
 'bid': 8.08,
 'bidSize': 1300,
 'bookValue': 3.813,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rehovot',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8.93,
 'dayLow': 8.68,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 0.06,
 'enterpriseToEbitda': 11.403,
 'enterpriseToRevenue': 2.222,
 'enterpriseValue': 297088160,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 8 940 6473',
 'fiftyDayAverage': 8.51,
 'fiftyTwoWeekHigh': 9.91,
 'fiftyTwoWeekLow': 4.4,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 27359713,
 'forwardEps': -0.04,
 'forwardPE': -217.00002,
 'fromCurrency': None,
 'fullTimeEmployees': 429,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.19820999,
 'heldPercentInstitutions': 0.38755,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kamada.com',
 'longBusinessSummary': 'Kamada Ltd. develops, produces, and markets '
                        'plasma-derived protein therapeutics for orphan '
                        'indications. It operates in two segments, Proprietary '
                        'Products and Distribution. The company offers '
                        'respiratory products, including Glassia for use in '
                        'chronic augmentation and maintenance therapy in '
                        'adults with emphysema due to congenital Alpha-1 '
                        'Antitrypsin (AAT) deficiency. It also provides KamRAB '
                        'for prophylaxis of rabies disease; KamRho (D) IM to '
                        'treat prophylaxis of hemolytic disease of newborns; '
                        'KamRho (D) IV for immune thermobocytopunic purpura; '
                        'and snake bite antiserum to treat snake bites by the '
                        'vipera palaestinae and echis coloratus, as well as '
                        'human transferrin that is used as a cultural medium '
                        'for diagnostic assays and cell cultures. In addition, '
                        'the company distributes Bramitob to manage chronic '
                        'pulmonary infection; FOSTER to treat asthma; '
                        'PROVOCHOLINE for the diagnosis of bronchial airway '
                        'hyperactivity; IVIG 5% for the treatment of various '
                        'immunodeficiency-related conditions; Varitect, a '
                        'varicella zoster immunoglobulin; Zutectra and '
                        'Hepatect CP for the prevention of hepatitis B virus; '
                        'Megalotect, a CMV immunoglobulin; and RUCONEST for '
                        'the treatment of acute angioedema attacks in adults '
                        'with hereditary angioedema. Further, it distributes '
                        'Heparin sodium injection to treat thrombo-embolic '
                        'disorders; Albumin and Albumin 4% for maintenance of '
                        'blood plasma; and coagulation factors comprising '
                        'Factor VIII and Factor IX, as well as IXIARO vaccine. '
                        "The company's products in pipeline are G1-AAT (IV) "
                        'for graft versus host disease and L1-AAT (1V) for '
                        'lung transparent that are in Phase II stage; and '
                        'Inhaled AAT for AAT deficiency, which is in Phase II '
                        'and III stages. It markets its products through '
                        'strategic partners in the United States, as well as '
                        'through distributors internationally. Kamada Ltd. has '
                        'strategic partnerships with Takeda Pharmaceutical '
                        'Company Limited; PARI GmbH; and Kedrion Biopharma. '
                        'The company was founded in 1990 and is headquartered '
                        'in Rehovot, Israel.',
 'longName': 'Kamada Ltd.',
 'market': 'us_market',
 'marketCap': 386598528,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9002466',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 22546000,
 'nextFiscalYearEnd': 1640908800,
 'open': 8.93,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 4.65,
 'phone': '972 8 940 6472',
 'previousClose': 8.93,
 'priceHint': 2,
 'priceToBook': 2.276423,
 'priceToSalesTrailing12Months': 2.89197,
 'profitMargins': 0.16865999,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8.93,
 'regularMarketDayLow': 8.68,
 'regularMarketOpen': 8.93,
 'regularMarketPreviousClose': 8.93,
 'regularMarketPrice': 8.93,
 'regularMarketVolume': 49418,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44524000,
 'sharesPercentSharesOut': 0.003,
 'sharesShort': 133576,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 89448,
 'shortName': 'Kamada Ltd.',
 'shortPercentOfFloat': 0.0047,
 'shortRatio': 0.71,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'KMDA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.549,
 'trailingPE': 15.810564,
 'twoHundredDayAverage': 7.034676,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'a88fd904-380d-3754-b686-3fbaf4e080d7',
 'volume': 49418,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kamada.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '7670402'}